证券代码：301009 证券简称：可靠股份 公告编号：2026-005 杭州可靠护理用品股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 1 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公 司规范运作》及《公司章程》的相关规定，上述日常关联交易事项未达到股东会 审批权限，无需提交股东会审议。 （二）2026 年度预计日常关联交易类别和金额 单位：万元 （一）日常关联交易概述 杭州可靠护理用品股份有限公司（以下简称"公司"或"可靠股份"）于 2026 年 1 月 30 日召开了第五届董事会第十六次（临时）会议，审议通过了《关 于 2026 年度日常关联交易预计的议案》，同意 2026 年度日常关联交易预计额度 不超过 6,168 万元。具体情况如下： 公司及控股子公司结合日常经营和业务发展需要，预计 2026 年度拟发生以 下关联交易： 1、公司控股子公司杭州可芯美登材料科技有限公司（以下简称"可芯美登"） 与公司关联方杭州侨治投资有限公司（以下简称"侨 ...

证券代码：301009 证券简称：可靠股份 公告编号：2026-004 杭州可靠护理用品股份有限公司 第五届董事会第十六次（临时）会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 杭州可靠护理用品股份有限公司（以下简称"公司"或"可靠股份"）第五 届董事会第十六次（临时）会议于 2026 年 1 月 30 日在杭州市余杭区向往街 1118 号英国中心 T6-28 层公司会议室以现场结合网络会议方式召开，会议通知已于 2026 年 1 月 27 日以电话及电子邮件等方式送达全体董事。本次会议应出席董事 7 人，实际出席董事 7 人（其中董事鲍佳女士、独立董事寿泓先生、独立董事肖 炜麟先生、独立董事景乃权先生以网络会议方式审议表决），会议由董事长金利 伟先生主持，公司高级管理人员列席。会议召开符合有关法律、法规、规章和《公 司章程》的规定。 二、董事会会议审议情况 表决结果：同意 4 票，反对 1 票，弃权 0 票，获得通过。 1、审议通过《关于 2026 年度日常关联交易预计的议案》 经审议，公司 2026 年度预计发生的日常 ...

北京商报讯(记者王寅浩宋雨盈)1月30日，百利天恒发布2025年业绩预告，预计2025年实现营业收入25 亿元左右，同比减少57.06%左右；预计实现归属于母公司所有者的净亏损为11亿元左右，同比减少 129.67%左右；预计实现归属于母公司所有者扣除非经常性损益后的净亏损为12亿元左右，同比减少 133.01%左右。 根据公告，业绩变动系报告期内，公司持续加大研发投入，导致研发投入同比增幅较大。同时，上年同 期收到BMS首付款所确认的知识产权收入大于报告期内确认的里程碑收入。 ...

Market Overview - The personal care products sector experienced a decline of 1.66% on January 30, with Zhongshun Jierou leading the drop [1] - The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1] Stock Performance - The following stocks in the personal care sector showed notable performance: - Beijiajie (603059) increased by 10.00% to a closing price of 37.29, with a trading volume of 32,300 hands and a turnover of 118 million [1] - Reliable Co. (301009) rose by 1.21% to 13.38, with a trading volume of 32,700 hands and a turnover of 43.52 million [1] - Liangmian Needle (600249) saw a slight increase of 0.51% to 5.92, with a trading volume of 112,700 hands and a turnover of 66.34 million [1] - Zhongshun Jierou (002511) fell by 5.45% to 8.15, with a trading volume of 482,800 hands and a turnover of 400 million [2] Capital Flow - The personal care products sector experienced a net outflow of 105 million from institutional investors, while retail investors saw a net inflow of 42.76 million [2] - The following stocks had significant capital flow: - Beijiajie (603059) had a net inflow of 20.94 million from institutional investors, but a net outflow of 15.94 million from retail investors [3] - Zhongshun Jierou (002511) faced a net outflow of 21.64 million from institutional investors [3] - Reliable Co. (301009) had a minor net inflow of 0.57 million from institutional investors [3]

Market Overview - The personal care products sector experienced a decline of 1.62% on January 28, with Yanjiang Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] Stock Performance - The following stocks in the personal care sector showed notable price changes: - Zhongshun Jiesang: Closed at 8.58, up 0.70% with a trading volume of 244,800 shares and a turnover of 209 million yuan [1] - Yanjiang Co., Ltd.: Closed at 16.40, down 6.23% with a trading volume of 426,300 shares and a turnover of 73 million yuan [2] - Beijia Clean: Closed at 34.18, down 3.77% with a trading volume of 31,400 shares and a turnover of 109 million yuan [2] Capital Flow - The personal care products sector saw a net outflow of 111 million yuan from institutional investors, while retail investors had a net inflow of 1.05 billion yuan [2] - The following stocks had significant capital flow: - Zhongshun Jiesang: Net inflow from institutional investors was 5.43 million yuan, with a retail net inflow of 15.08 million yuan [3] - Yanjiang Co., Ltd.: Experienced a net outflow of 1.25 million yuan from institutional investors [3] - Beijia Clean: Had a net outflow of 2.60 million yuan from institutional investors, but a net inflow of 12.19 million yuan from retail investors [3]

Market Overview - The personal care products sector experienced a decline of 1.53% on January 27, with Yanjiang Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Stock Performance - Notable stock performances include: - Dengkang Oral Care (001328) closed at 40.93, up 1.99% with a trading volume of 15,900 shares and a turnover of 64.67 million yuan [1] - Beijia Clean (603059) closed at 35.52, up 0.45% with a trading volume of 22,500 shares and a turnover of 79.75 million yuan [1] - Yanjiang Co., Ltd. (300658) closed at 17.49, down 6.02% with a trading volume of 404,000 shares and a turnover of 702 million yuan [2] Capital Flow - The personal care products sector saw a net outflow of 73.09 million yuan from institutional investors, while retail investors had a net inflow of 85.19 million yuan [2] - The capital flow for individual stocks shows: - Zhongshun Jierou (002511) had a net inflow of 4.92 million yuan from retail investors, but a net outflow of 1.30 million yuan from institutional investors [3] - Other stocks like Yiyi Co., Ltd. (001206) and Jeya Co., Ltd. (301108) also experienced significant net outflows from institutional investors [3]

Market Overview - The personal care products sector experienced a decline of 0.16% on January 26, with Beijia leading the drop [1] - The Shanghai Composite Index closed at 4132.61, down 0.09%, while the Shenzhen Component Index closed at 14316.64, down 0.85% [1] Stock Performance - Notable stock performances include: - Yanjing Co. (300658) closed at 18.61, up 2.14% with a trading volume of 489,900 shares and a transaction value of 917 million yuan [1] - Stable Medical (300888) closed at 37.61, up 1.81% with a trading volume of 86,900 shares and a transaction value of 326 million yuan [1] - Beijia (603059) closed at 35.36, down 5.07% with a trading volume of 25,900 shares and a transaction value of 92.56 million yuan [2] Capital Flow - The personal care products sector saw a net inflow of 72.66 million yuan from institutional investors, while retail investors experienced a net outflow of 72.01 million yuan [2] - The capital flow for individual stocks includes: - Yanjing Co. had a net inflow of 10.5 million yuan from institutional investors [3] - Stable Medical had a net inflow of 12.15 million yuan from institutional investors [3] - Beijia experienced a net outflow of 5.37 million yuan from institutional investors [3]

Market Overview - The personal care products sector increased by 0.03% on January 23, with Runben Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 4136.16, up by 0.33%, while the Shenzhen Component Index closed at 14439.66, up by 0.79% [1] Stock Performance - Runben Co., Ltd. (603193) closed at 25.71, with a rise of 1.78% and a trading volume of 41,300 shares, totaling 106 million yuan [1] - Other notable performers include: - Wanjian Medical (300888) at 36.94, up 1.40% with a trading volume of 50,800 shares, totaling 187 million yuan [1] - Yiyi Co., Ltd. (001206) at 28.47, up 1.10% with a trading volume of 21,800 shares, totaling 61.78 million yuan [1] - Home Care (605009) at 32.39, up 0.90% with a trading volume of 16,200 shares, totaling 52.33 million yuan [1] Capital Flow - The personal care products sector experienced a net outflow of 75.43 million yuan from institutional investors, while retail investors saw a net inflow of 85.32 million yuan [2] - The capital flow for individual stocks shows: - Runben Co., Ltd. had a net inflow of 5.90 million yuan from institutional investors [3] - Wanjian Medical had a net inflow of 4.50 million yuan from institutional investors [3] - Yiyi Co., Ltd. had a net inflow of 1.62 million yuan from retail investors [3]

证券代码：301009 证券简称：可靠股份 公告编号：2026-003 杭州可靠护理用品股份有限公司 一、董事会会议召开情况 杭州可靠护理用品股份有限公司（以下简称"公司"）第五届董事会第十五 次（临时）会议于 2026 年 1 月 23 日在杭州市余杭区向往街 1118 号英国中心 T6-28 层公司会议室以现场结合网络会议方式召开，会议通知已于 2026 年 1 月 19 日以 电话及电子邮件等方式送达全体董事。本次会议应出席董事 7 人，实际出席董事 7 人（其中董事鲍佳女士、独立董事寿泓先生、独立董事肖炜麟先生以网络会议 方式审议表决，独立董事景乃权先生授权委托独立董事寿泓先生代为出席并行使 表决权），会议由董事长金利伟先生主持，公司部分高级管理人员列席。会议召 开符合有关法律、法规、规章和《公司章程》的规定。 二、董事会会议审议情况 1、审议通过《关于选举代表公司执行公司事务的董事的议案》 经与会董事审议，根据相关监管要求及公司经营发展需要，依据《中华人民 共和国公司法》《上市公司章程指引》和《公司章程》的有关规定，同意选举董 事长金利伟先生为代表公司执行公司事务的董事，并担任公司法定代表人，任期 ...

Core Viewpoint - Bailitianheng is a comprehensive enterprise focusing on cutting-edge global biomedicine, particularly in the field of tumor macromolecule therapy, with a strategic goal of becoming a multinational corporation (MNC) dedicated to addressing unmet clinical needs in cancer treatment [1] Group 1: Company Overview - Bailitianheng specializes in innovative research and development, global clinical development, and large-scale production capabilities in the tumor macromolecule therapy sector [1] - The company aims to build a full industry chain covering research, clinical trials, production, and commercialization, aspiring to become a leading multinational pharmaceutical enterprise in cancer treatment [1] Group 2: Clinical Needs and Innovations - Nasopharyngeal carcinoma is a highly prevalent malignant tumor in China, with limited treatment options for late-stage patients, highlighting a significant clinical need for new therapeutic mechanisms [1] - In addition to nasopharyngeal carcinoma, China has the highest incidence and mortality rates for esophageal cancer globally, with a pressing demand for effective second-line treatment options [1] Group 3: Product Development - Bailitianheng has developed iza-bren, a first-in-class EGFR×HER3 dual-target ADC drug, which is currently the only dual-target ADC in Phase III clinical trials [2] - Iza-bren utilizes a dual-target design to precisely deliver cytotoxic payloads to tumor cells while minimizing damage to normal cells, enhancing efficacy and reducing adverse reactions [2] Group 4: Clinical Trial Results - The Phase III study BL-B01D1-303 for recurrent or metastatic nasopharyngeal carcinoma patients showed a 54.6% objective response rate (ORR), significantly higher than the 27.0% for standard chemotherapy, and a median progression-free survival (mPFS) of 8.38 months compared to 4.34 months for chemotherapy [3] - The study results have been recognized internationally, with findings selected for presentation at the 2025 ESMO conference and published in The Lancet [3] Group 5: Regulatory Progress - Iza-bren has been included in the priority review list by the CDE and has received acceptance for its new drug application for nasopharyngeal carcinoma by the NMPA [3] - The Phase III study BL-B01D1-305 for esophageal squamous cell carcinoma achieved positive results for both progression-free survival (PFS) and overall survival (OS), marking a significant milestone for ADC drugs in this field [4] Group 6: Industry Impact - Iza-bren represents a successful example of clinical translation for dual-target ADC technology, showcasing Bailitianheng's research capabilities in tumor macromolecule therapy [4] - The successful commercialization of iza-bren is expected to reshape treatment paradigms for late-stage nasopharyngeal carcinoma and esophageal squamous cell carcinoma, providing new hope for patients who have failed previous treatments [4][5] Group 7: Future Outlook - With the commercialization of iza-bren and the advancement of more innovative pipelines, the company aims to lead the development of innovative cancer therapies and contribute to the global narrative of China's biopharmaceutical industry [5]